Translational Development...

NASDAQ: TDAC · Real-Time Price · USD
10.32
0.00 (0.00%)
At close: Aug 15, 2025, 10:41 AM

Translational Development Acquisition Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022
Revenue
n/a n/a n/a
Cost of Revenue
n/a n/a n/a
Gross Profit
n/a n/a n/a
Operating Income
-196.36K -485.55K -70.66K
Interest Income
n/a n/a n/a
Pretax Income
-71.01K -485.55K -70.66K
Net Income
-71.01K -485.55K -70.66K
Selling & General & Admin
196.36K 485.55K 70.66K
Research & Development
n/a n/a n/a
Other Expenses
n/a n/a n/a
Operating Expenses
196.36K 485.55K 70.66K
Interest Expense
n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
-196.36K 485.55K 70.66K
Income Tax Expense
n/a n/a n/a
Shares Outstanding (Basic)
4.05M 4.05M 4.05M
Shares Outstanding (Diluted)
4.05M 4.05M 4.05M
EPS (Basic)
-0.21 -0.12 -0.02
EPS (Diluted)
-0.21 -0.12 -0.02
EBITDA
-71.01K -485.55K n/a
EBIT
-71.01K -485.55K -70.66K
Depreciation & Amortization
n/a n/a 70.66K